Stoke Therapeutics, Inc. Net Income
Stoke Therapeutics, Inc. (STOK) reported Net Income of -$61.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-03
- Stoke Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$61.62M.
- Stoke Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$50.00M, a 144.30% decline year-over-year.
- Stoke Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$57.93M.
- Stoke Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$38.35M.
- Stoke Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2022 was -$101.07M.
- Stoke Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2021 was -$85.81M.
- Stoke Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2020 was -$52.24M.
- Stoke Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2019 was -$32.33M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$61.62M 10-Q · filed 2026-08-03 | -$111.62M 10-Q · filed 2026-08-03 | -$169.56M derived: sum of 3 quarters · filed 2026-08-03 | -$207.90M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$50.00M 10-Q · filed 2026-08-03 | -$107.94M derived: sum of 2 quarters · filed 2026-08-03 | -$146.28M derived: sum of 3 quarters · filed 2026-08-03 | -$169.77M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$57.93M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-22 | -$96.28M derived: sum of 2 quarters · filed 2026-04-22 | -$119.76M derived: sum of 3 quarters · filed 2026-08-03 | -$6.88M DEF 14A · filed 2026-04-22 |
| 2025-09-30 | -$38.35M 10-Q · filed 2025-11-04 | -$61.83M derived: sum of 2 quarters · filed 2026-08-03 | $51.05M 10-Q · filed 2025-11-04 | $40.57M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$23.48M 10-Q · filed 2026-08-03 | $89.40M 10-Q · filed 2026-08-03 | $78.91M derived: sum of 3 quarters · filed 2026-08-03 | $52.48M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $112.88M 10-Q · filed 2026-08-03 | $102.40M derived: sum of 2 quarters · filed 2026-08-03 | $75.97M derived: sum of 3 quarters · filed 2026-08-03 | $50.27M derived: sum of 4 quarters · filed 2026-08-03 |
| 2024-12-31 | -$10.48M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-22 | -$36.91M derived: sum of 2 quarters · filed 2026-04-22 | -$62.61M derived: sum of 3 quarters · filed 2026-04-22 | -$88.98M DEF 14A · filed 2026-04-22 |
| 2024-09-30 | -$26.43M 10-Q · filed 2025-11-04 | -$52.13M derived: sum of 2 quarters · filed 2025-11-04 | -$78.50M 10-Q · filed 2025-11-04 | -$105.46M derived: sum of 4 quarters · filed 2026-04-22 |
| 2024-06-30 | -$25.70M 10-Q · filed 2025-11-04 | -$52.07M 10-Q · filed 2025-08-12 | -$79.03M derived: sum of 3 quarters · filed 2026-04-22 | -$103.57M derived: sum of 4 quarters · filed 2026-04-22 |
| 2024-03-31 | -$26.37M 10-Q · filed 2025-11-04 | -$53.33M derived: sum of 2 quarters · filed 2026-04-22 | -$77.87M derived: sum of 3 quarters · filed 2026-04-22 | -$108.53M derived: sum of 4 quarters · filed 2026-04-22 |
| 2023-12-31 | -$26.96M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-22 | -$51.50M derived: sum of 2 quarters · filed 2026-04-22 | -$82.15M derived: sum of 3 quarters · filed 2026-04-22 | -$104.70M DEF 14A · filed 2026-04-22 |
| 2023-09-30 | -$24.54M 10-Q · filed 2024-11-05 | -$55.20M derived: sum of 2 quarters · filed 2024-11-05 | -$77.74M 10-Q · filed 2024-11-05 | -$103.40M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$30.65M 10-Q · filed 2024-11-05 | -$53.20M 10-Q · filed 2024-08-07 | -$78.85M derived: sum of 3 quarters · filed 2024-11-05 | -$104.97M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-03-31 | -$22.55M 10-Q · filed 2024-11-05 | -$48.20M derived: sum of 2 quarters · filed 2024-11-05 | -$74.31M derived: sum of 3 quarters · filed 2024-11-05 | -$98.96M derived: sum of 4 quarters · filed 2024-11-05 |
| 2022-12-31 | -$25.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$51.77M derived: sum of 2 quarters · filed 2024-03-25 | -$76.42M derived: sum of 3 quarters · filed 2024-03-25 | -$101.07M 10-K · filed 2024-03-25 |
| 2022-09-30 | -$26.11M 10-Q · filed 2023-11-07 | -$50.76M derived: sum of 2 quarters · filed 2023-11-07 | -$75.41M 10-Q · filed 2023-11-07 | -$99.86M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$24.65M 10-Q · filed 2023-11-07 | -$49.30M 10-Q · filed 2023-08-07 | -$73.75M derived: sum of 3 quarters · filed 2023-11-07 | -$96.35M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-03-31 | -$24.65M 10-Q · filed 2023-11-07 | -$49.10M derived: sum of 2 quarters · filed 2023-11-07 | -$71.69M derived: sum of 3 quarters · filed 2023-11-07 | -$93.66M derived: sum of 4 quarters · filed 2023-11-07 |
| 2021-12-31 | -$24.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$47.05M derived: sum of 2 quarters · filed 2023-03-06 | -$69.01M derived: sum of 3 quarters · filed 2023-03-06 | -$85.81M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$22.60M 10-Q · filed 2022-11-14 | -$44.56M derived: sum of 2 quarters · filed 2022-11-14 | -$61.36M 10-Q · filed 2022-11-14 | -$75.92M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$21.97M 10-Q · filed 2022-11-14 | -$38.76M 10-Q · filed 2022-08-08 | -$53.32M derived: sum of 3 quarters · filed 2022-11-14 | -$67.00M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-03-31 | -$16.79M 10-Q · filed 2022-11-14 | -$31.35M derived: sum of 2 quarters · filed 2022-11-14 | -$45.04M derived: sum of 3 quarters · filed 2022-11-14 | -$58.00M derived: sum of 4 quarters · filed 2022-11-14 |
| 2020-12-31 | -$14.56M 10-K · filed 2021-03-09 | -$28.25M derived: sum of 2 quarters · filed 2021-11-08 | -$41.20M derived: sum of 3 quarters · filed 2021-11-08 | -$52.24M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$13.68M 10-Q · filed 2021-11-08 | -$26.64M derived: sum of 2 quarters · filed 2021-11-08 | -$37.68M 10-Q · filed 2021-11-08 | -$47.84M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | -$12.96M 10-Q · filed 2021-11-08 | -$24.00M 10-Q · filed 2021-08-10 | -$34.16M derived: sum of 3 quarters · filed 2021-11-08 | -$42.76M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-03-31 | -$11.04M 10-Q · filed 2021-11-08 | -$21.20M derived: sum of 2 quarters · filed 2021-11-08 | -$29.80M derived: sum of 3 quarters · filed 2021-11-08 | -$37.62M derived: sum of 4 quarters · filed 2021-11-08 |
| 2019-12-31 | -$10.16M 10-K · filed 2021-03-09 | -$18.76M derived: sum of 2 quarters · filed 2021-03-09 | -$26.58M derived: sum of 3 quarters · filed 2021-03-09 | -$32.33M 10-K · filed 2021-03-09 |
| 2019-09-30 | -$8.60M 10-K · filed 2021-03-09 | -$16.42M derived: sum of 2 quarters · filed 2021-03-09 | -$22.16M 10-Q · filed 2020-11-12 | -$26.45M derived: sum of 4 quarters · filed 2021-03-09 |
| 2019-06-30 | -$7.82M 10-K · filed 2021-03-09 | -$13.56M 10-Q · filed 2020-08-10 | -$17.84M derived: sum of 3 quarters · filed 2021-03-09 | -$21.16M derived: sum of 4 quarters · filed 2021-03-09 |
| 2019-03-31 | -$5.74M 10-K · filed 2021-03-09 | -$10.02M derived: sum of 2 quarters · filed 2021-03-09 | -$13.34M derived: sum of 3 quarters · filed 2021-03-09 | -$16.35M derived: sum of 4 quarters · filed 2021-03-09 |
| 2018-12-31 | -$4.28M 10-K · filed 2020-03-23 | -$7.60M derived: sum of 2 quarters · filed 2020-03-23 | -$10.61M derived: sum of 3 quarters · filed 2020-03-23 | -$12.52M 10-K · filed 2020-03-23 |
| 2018-09-30 | -$3.32M 10-K · filed 2020-03-23 | -$6.33M derived: sum of 2 quarters · filed 2020-03-23 | -$8.24M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$3.01M 10-K · filed 2020-03-23 | -$4.92M 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | -$1.91M 10-K · filed 2020-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |